Microbix Biosystems Inc. Announces Extension and Re-Pricing of Share Purchase Warrants

Published: Nov 02, 2012

Microbix Biosystems Inc. (TSX:MBX) is pleased to announce it has made application to the TSX to extend the term and amend the exercise price of an aggregate of 3,250,000 common share purchase warrants (the "Warrants") which were issued in connection with Microbix's November 13, 2007 private placement.

Each Warrant currently entitles the holder to purchase one common share of Microbix at a price of $1.26 until November 13, 2012. Microbix has applied to the TSX to extend the term of the Warrants to November 13, 2013 and to re-price the Warrants from $1.26 to $0.40 per share.

The holders of the Warrants are all arm's length to Microbix. The amendments to the Warrants are subject to TSX approval.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. specializes in the development of the most advanced vaccine production technology and markets virology and biological products worldwide. In addition, The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Microbix supplies customers in the U.S., Europe, and Asia. Established in 1988, Microbix is headquartered in Toronto.


This press release may contain forward-looking statements which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with development projects, operations in foreign jurisdictions, risks associated with engineering and construction generally, risks associated with production including control over costs, quality, quantity and timeliness of delivery of products, foreign currency and exchange rate risk, and risks of raising capital on acceptable terms or at all. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Microbix Biosystems Inc.

Visit www.microbix.com or contact: William J. Gastle, CEO, (416) 234-1624 x 230; or James Long, CFO, (416) 234-1624 x 265

Back to news